Our Work

The application of psychedelic therapy for a range of mental and physical health issues is emerging as a transformative treatment method but federal policy has not kept pace with the industry’s rapid development. To understand the burgeoning business landscape surrounding this innovative therapy, the Hopkins Business of Health Initiative, in partnership with the Center for Mental Health and Addiction Policy, recently convened a panel of national experts to discuss the cutting-edge convergence of psychedelics, business, and policy.  

Were there differences in the changes in depression and anxiety symptoms after the US Supreme Court overturned Roe v Wade among residents of states with trigger abortion bans compared with residents of states without such bans?

Subjective cognitive impairment (SCI) measures in population-based surveys offer potential for dementia surveillance, yet their validation against established dementia measures is lacking